iiinova — where your digital self keeps evolving

Reposted by Gustavo Baldassarre

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 07/09/2026

Platinum resistance limits effective treatment for #OvarianCancer. CDK12i synergizes with Pt-therapy disrupting transcriptional elongation and SFPQ/p54nrb-dependent #AlternativeSplicing, highlighting it as a potent therapeutic strategy. #STTT #OpenAccess: doi.org/10.1038/s413...

CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism

013

Gustavo Baldassarre @gusbald.bsky.social · 09/06/2026

Submit your abstract at BIG2026 and win a night in Venice #gynecology_oncology #cancer_research #clinical_development For more info ecm.meetingsrl.eu/BIG2026/regi...

010

Gustavo Baldassarre @gusbald.bsky.social · 08/06/2026

BiG 2026 is approaching. Join us in Venice Italy on September 24-25 for a really beautiful, informative and friendly meeting with top scientists in the field of clinical and translational gynecology oncology!

100

Gustavo Baldassarre @gusbald.bsky.social · 11/05/2026

sic2026.cancerologia.it Don’t miss the opportunity to share your research in an inclusive and exciting meeting! We hope to meet you all in Rome at #SIC_2026

sic2026.cancerologia.it

SIC 2026 – 66th Annual Meeting of the Italian Cancer Society

000

Reposted by Gustavo Baldassarre

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 06/05/2026

If you are interested in PARP inhibitors and history, this might be of interest to you. www.nature.com/articles/s41.... An attempt to cover the work of thousands and their immense contributions to the development of a targeted approach to treating cancers.

nature.com

Two decades of PARP inhibitor synthetic lethality in cancer - Nature

The past two decades of PARP inhibitor synthetic lethality in cancer is explored.

01510

Reposted by Gustavo Baldassarre

The Lancet @thelancet.com · 17/04/2026

Epithelial ovarian cancer frequently recurs and becomes resistant to platinum chemotherapy. In our latest issue, two separate phase 3 trials highlight two potential new treatments for platinum-resistant ovarian cancer. Read this & more ▶️ spkl.io/63325A4OfN

Cover of The Lancet's April 18, 2026 issue. Quote on cover reads: "Platinum-resistant ovarian cancer is a leading cause of gynaecological cancer-related mortality worldwide".

0125

Reposted by Gustavo Baldassarre

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 30/03/2026

A comprehensive analysis of cyclin-dependent kinases in #CellCycle regulation, detailing how their dysregulation drives disease and evaluating the therapeutic potential of targeted CDK inhibitors. @gusbald.bsky.social @gustavo_baldassarre #OpenAccess: doi.org/10.1038/s413...

021

Reposted by Gustavo Baldassarre

Yoda @politicaperjedi.bsky.social · 22/03/2026

Lev Tolstoj, Resurrezione.

3317

Reposted by Gustavo Baldassarre

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 11/10/2025

A review of the functions of human #CyclinDependentKinases, highlighting their roles in #cellcycle control, disease progression, & the therapeutic potential of #CDKInhibitors in #cancer & other diseases. @gusbald.bsky.social #STTT: doi.org/10.1038/s413...

041

Gustavo Baldassarre @gusbald.bsky.social · 10/09/2025

Great presentation at #CRO_Aviano_IRCCS by @biancastellac.bsky.social on genetic and #epigenetic alterations in #breast tissue. Thank you Biancastella, it was wonderful have you in Aviano!

010

Reposted by Gustavo Baldassarre

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 13/08/2025

This review summarizes the functions of #CyclinDependentKinases (CDKs), discusses their potential roles and deregulation in human pathologies and underscores the role of CDK inhibitors as standard therapies in #cancer. #medsky @gusbald.bsky.social @gustavo_baldassarre #OpenAccess: buff.ly/NA2B1Fs

021

Gustavo Baldassarre @gusbald.bsky.social · 10/08/2025

Sunset from #Monte_Faito #Campania #Italy. From right to left you can admire the Vesuvius Vulcan, Monte di Procida, the islands Procida, Ischia and Capri and the peninsula Sorrentina. This is the magnificent #gulf_of_Napoli

010

Gustavo Baldassarre @gusbald.bsky.social · 16/05/2025

Just out in #Molecular_Cancer a beautiful journey with Ivana de la Serna and Francois Vallette discussing #cancer_cells #clonal_evolution and #resistance to treatments from 3 different and complementary points of view. Hope you will enjoy read this review as we enjoyed writing it. rdcu.be/emfur

rdcu.be

Death-ision: the link between cellular resilience and cancer resistance to treatments

000

Gustavo Baldassarre @gusbald.bsky.social · 10/05/2025

Free registration open for BIG2025. Limited on site places. All info on: 👇 ecm.meetingsrl.eu/BIG2025/defa... Registration for ITALIAN PARTICIPANT 👇 ecm.meetingsrl.eu/BIG2025/defa... Registration forFOREIGN PARTICIPANT 👇 www.meetingsrl.eu/registration... Meet the speakers See you in Venice

020

Gustavo Baldassarre @gusbald.bsky.social · 10/05/2025

010

Gustavo Baldassarre @gusbald.bsky.social · 09/05/2025

Here we are! Registration for BIG 2025 is now open. All info on: 👇 ecm.meetingsrl.eu/BIG2025/defa... Registration for ITALIAN PARTICIPANT 👇 ecm.meetingsrl.eu/BIG2025/defa... Registration forFOREIGN PARTICIPANT 👇 www.meetingsrl.eu/registration... See you in Venice

ecm.meetingsrl.eu

Ecm Platform

FAD, ecm

000

Gustavo Baldassarre @gusbald.bsky.social · 26/04/2025

The 4th edition of BIG is approaching. An exceptional panel of speakers discussing the novelties in #translational and #clinical #gynecology_oncology. Free registration but limited places. Below, you can see the venue and meet the organizers. Stay tuned for updates. See you in #Venice

000

Reposted by Gustavo Baldassarre

Science Friday @scifri.bsky.social · 16/03/2025

90% of people diagnosed with pancreatic cancer die from the disease. That's why the medical community is excited about the results of a small trial in which nearly half of the pancreatic cancer patients who received an mRNA vaccine for the disease remained relapse-free three years later.

sciencefriday.com

A Vaccine For Pancreatic Cancer Continues To Show Promise

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.

819325157643

Gustavo Baldassarre @gusbald.bsky.social · 06/03/2025

The 4th edition of BIG is approaching. Don’t miss the opportunity to joining us and meet an exceptional panel of speakers in the wonderful city of Venice. Stay tuned for further updates

000

Reposted by Gustavo Baldassarre

Alex Merz 🇺🇸🇨🇦🇺🇦 @merz.bsky.social · 01/03/2025

Right now, I can't open: www.nlm.nih.gov ftp.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov/genbank/ pubmed.ncbi.nlm.nih.gov

121811

Reposted by Gustavo Baldassarre

Etienne Bucher 🌾🧬🇪🇺 @plantepigenetics.ch · 02/03/2025

As we can expect PubMed dysfunction more and more or to be swamped with fake journals I suggest you get acquainted to this nice alternative: europepmc.org

europepmc.org

Europe PMCHome - Europe PMC

Europe PMC is an archive of life sciences journal literature.

11428156

Reposted by Gustavo Baldassarre

Surfin' NuRD @surfinnurd.bsky.social · 02/03/2025

Remember, EuropePMC is actually better than #PubMed because it includes ALL preprints in search results, not just those including NIH-funded research. europepmc.org

europepmc.org

Europe PMCHome - Europe PMC

Europe PMC is an archive of life sciences journal literature.

11474175

Gustavo Baldassarre @gusbald.bsky.social · 15/02/2025

Enjoying skiing on Dolomiti alps in a sunny, cold Saturday with old friends! What a day!

000

Reposted by Gustavo Baldassarre

Gustavo Baldassarre @gusbald.bsky.social · 14/01/2025

What a great start to 2025 having our review on the role of hashtag#CDKs in human physiology and diseases just published in #Signal_Transduction_Targeted_Therapies! Here is the link to the open access article 👇 rdcu.be/d6a4g A big effort of the lab but we learnt a lot! I hope you will enjoy it

rdcu.be

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

Signal Transduction and Targeted Therapy - Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

093

Gustavo Baldassarre @gusbald.bsky.social · 14/01/2025

rdcu.be

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

Signal Transduction and Targeted Therapy - Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

093

Reposted by Gustavo Baldassarre

The Daily Pub @thedailypub.bsky.social · 13/01/2025

Cyclin Dependent Kinases (CDKs) are crucial for cell division and exist in 20 variations, each with unique roles. Their malfunction is linked to diseases like cancer and Alzheimer's. CDK inhibitors are now cancer treatments, and exploring their use in other diseases could help improve patient care.

doi.org

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.

Published in Signal transduction and targeted therapy

011

Reposted by Gustavo Baldassarre

Jon Douglas @atranscendedman.bsky.social · 13/01/2025

Scientists in Italy show how cyclin-dependent kinases (CDKs) regulate cell division, gene expression, and DNA repair. Disrupted CDKs fuel diseases like cancer, making them critical targets for therapy. www.nature.com/articles/s41...

nature.com

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease - Signal Transduction and Targeted Therapy

Signal Transduction and Targeted Therapy - Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

021

Reposted by Gustavo Baldassarre

Ronny Drapkin @rdrapkin8-penn.bsky.social · 24/12/2024

This paper is the result of an incredibly fun collaboration with Sandro Santagata and Peter Sorger. Led by an amazing postdoc @tanjinakader.bsky.social and JiaRen Lin, we provide a pre-cancer atlas of Fallopian tube precursors to High-Grade Serous Ovarian Cancer. The data is also on cbioportal!

0255

Reposted by Gustavo Baldassarre

Elizabeth McKenna @elizsmckenna.bsky.social · 20/12/2024

Now online in Cancer Discovery: Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma - by Tanjina Kader, Jia-Ren Lin, Clemens Hug, Ronny Drapkin, Sandro Santagata, et al. doi.org/10.1158/2159...

Schematic representation of HGSCO progression, emphasizing the temporal development of hallmark cancer features and the dynamic interplay and interactions between immune cells and precancer/cancer
cells. Cancer often starts with oncogenic changes (mutations, aneuploidy, and other cancer hallmarks), under selective pressure. These cells may remain latent for decades. Only a subset of these
“phenotypically normal” but mutated clones undergo clonal expansion and acquire additional mutations, ultimately developing into cancer. Early on, despite limited genomic instability, innate immune responses, including the NK-cDC1-CTL axis and tissue-resident memory T cells (TRM), help contain p53 signature cells. Increasing aneuploidy or extrinsic factors can enhance immune surveillance, potentially eliminating precancer clones before significant proliferation occurs. During early STIC expansion, there is pronounced IFN response activation, with activated cDC1 and APCs, and NK cell-secreted chemokines, further attracting cDC1. This environment suggests active immune surveillance and is accompanied by interactions among APCs, activated CD4+, and CD8+ T cells. However, immunosuppressive cells, such as M2-like macrophages and Tregs, also emerge, indicating a complex equilibrium where cytotoxic and suppressive forces coexist. As STIC lesions advance, there is a reduction in CD8+ T cells and the interactions between APCs and CD4 T cells, along with an increase in exhausted CD8+ CTL and CD4+ cells expressing LAG3, almost no NK and cDC1 cells, and more suppressive APCs. The transition from STIC to overt cancer involves hallmark mechanisms such as TGF-β signaling, which excludes CTLs, changes in cytokine and fibroblast profiles, and induction of EMT and migratory programs. Dotted arrows indicate the hypothetical timing of these events, suggesting a prolonged interval from p53 signature to early STIC, followed by a more rapid progression from early to late STIC.

2346

Reposted by Gustavo Baldassarre

Pills of Science🧬 @pillsofscience.bsky.social · 17/12/2024

Il mondo novax ha costruito una intera narrazione sull'efficacia e utilità dell'idrossiclorochina e azitromicina contro COVID-19. Ora lo studio "Principe" è stato ritirato.

1431793

Gustavo Baldassarre @gusbald.bsky.social · 02/12/2024

Today we celebrate the first 40 years of our institute Centro di Riferimento Oncologico CRO-Aviano National Cancer Institute. 40 beautiful years of research and cure in oncology in which we witnessed the advancements in the care for our patients.

000

Reposted by Gustavo Baldassarre

Lorenzo Piccoli @lorenzopiccoli.bsky.social · 02/12/2024

The SAFE project accepts applications for 60 fellowships for at-risk non-EU researchers (PhD/postdoc) to join research institutions in the EU. 🌍 Matchmaking support until 15 December 📅 Deadline: 20 Jan 2025 🔗 Learn more: saferesearchers.eu #ResearchOpportunities #AtRiskResearchers #SAFEFellowship

saferesearchers.eu

SAFE - Supporting  At-risk researchers  with Fellowships in Europe

As a pilot fellowship scheme, the SAFE project offers 60 fully-funded fellowships (up to 24 months) for doctoral and postdoctoral researchers of any non-EU nationality to work at a research institutio...

0911

Reposted by Gustavo Baldassarre

Netherlands Cancer Institute @nkinl.bsky.social · 27/11/2024

Delaying and shortening the duration of treatment with CDK4/6 inhibitors in patients with metastatic breast cancer leads to similar survival outcomes while reducing toxicity and achieving substantial cost savings, the SONIA trial shows. Read more ➡️ bit.ly/3Oqw7aX

04011

Reposted by Gustavo Baldassarre

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 21/11/2024

From @seedgeorge.bsky.social Johann De Bono and colleagues (us !). In BRCA2m CRPC, reversion mutations emerge in 79% by end of olaparib treatment. Reversions associate with PFS and OS. Rare subclones without BRCA2-loss also emerge authors.elsevier.com/sd/article/S...

authors.elsevier.com

ScienceDirect.com | Science, health and medical journals, full text articles and books.

1238

Reposted by Gustavo Baldassarre

EACR - European Association for Cancer Research @helloeacr.bsky.social · 21/11/2024

After a sold-out 2023 event, Goodbye Flat Biology has moved to a larger venue in Essen, Germany to make sure more of you can join us for what promises to be another fantastic event! Join us for 3 days of excellent science and networking: eacr.org/conference/g...

0109

Reposted by Gustavo Baldassarre

Angela Cheney @angela2932.bsky.social · 18/11/2024

I'm also trying to survive ovarian cancer, and research funds have been traditionally been so minimal for this disease. JJDiane, find ocrahope.org if you're not already familiar with it. Let's keep advocating together!

ocrahope.org

Ovarian Cancer Research Alliance

Ovarian Cancer Research Alliance (OCRA) is the largest global nonprofit advancing ovarian cancer research while supporting patients and their families.

021